A Phase 2, Multicenter, Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec in Subjects With Unresected, Stage IIIB to IVM1c Melanoma
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2019
Price : $35 *
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Malignant melanoma
- Focus Pharmacogenomic; Pharmacokinetics
- Sponsors Amgen
- 08 May 2018 Status changed from active, no longer recruiting to completed.
- 07 Feb 2018 Planned End Date changed from 28 Feb 2018 to 28 Aug 2018.
- 13 Dec 2017 Planned End Date changed from 29 Dec 2017 to 28 Feb 2018.